Fig. 7From: Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysisPooled effect estimates (log OR) for selected adverse events according to treatment groupBack to article page